NCT05131464View on ClinicalTrials.gov

The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
DRUG

CM310

CM310, 300 mg/2 mL, SC, every 2 weeks

Trial Locations (3)

Unknown

Beijing Tong-Ren hospital, Beijing

Site 3, Chengdu

Site 2, Wuhan

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05131464 - The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Biotech Hunter | Biotech Hunter